The Cardiology Show
Surrogate end points on trial: ENHANCE and other controversies
Nine of the world's top cardiologists gathered in Chicago to take on the issues raised by data released at the American College of Cardiology Scientific Sessions.

In Part 1 of the program, Dr Valentin Fuster moderates a frank and sometimes heated discussion, in which the panel argues, objects, and even comes close to consensus on the lessons to be learned from the ENHANCE controversy.
From ACC 2008: HAT; how does government select what trials to fund?
Findings from HAT released at ACC show no advantage to owning an AED for post-MI patients. Wasn't this predictable?

Dr Eric Topol invites you to share your thoughts on how government selects what trials to fund.

Click here to view the video blog and join the discussion.

Forum
Dr Melissa Walton-Shirley at the ACC
Join Forum Moderator Dr Melissa Walton-Shirley as she blogs from the floor of the convention center.
Thumbs up, thumbs down
Controversies: ENHANCE and ACCORD
Clinical trials are under attack and in the headlines. What is the proper role of the investigators? What are the responsibilities of industry? Join Drs Eric J Topol and Robert M Califf in a discussion of the many issues surrounding ENHANCE and ACCORD.
Cardiology panels
Getting the lowdown on HORIZONS
Drs Keith Fox and Gregg Stone go into the details of this practice-changing trial as they address concerns about acute stent thrombosis and talk about ways to improve outcomes, in a discussion moderated by Dr James Ferguson.
Debate continues over drug-eluting stents
Drs Gregg Stone and Renu Virmani share their hopes and concerns for PCI and drug-eluting stents as they weigh in on the COURAGE nuclear substudy and the latest registry data on DES vs bare-metal stents in a discussion moderated by heartwire journalist Shelley Wood.
Back to the ABCs for congestive heart failure?
Join Dr Melissa Walton-Shirley as she asks Drs Clyde Yancy and Roger Blumenthal for their thoughts on resynchronization therapy for narrow-QRS patients, the disappointing results with statins, and what to do with the T-wave alternans device you just ordered.
All about Eve: Treating women with ACS
Are women really different from men? Dr Melissa Walton-Shirley questions Drs William Boden and Judith Hochman on gender differences in the treatment of acute coronary syndrome.
Question
Do you think that IMPROVE-IT (the ezetimibe clinical outcomes trial scheduled to be completed in 2012) will show that ezetimibe reduces MACE?
(See:ENHANCE published, presented, discussed, and debated: Experts mull over what the findings mean)
Yes
No
Vote








Heparin deaths higher, FDA says
As many as 62 deaths over the past 15 months have been linked to tainted heparin on the basis of allergic/hypotensive symptoms, although heparin may not have actually caused the deaths.
To view the full text of this article, you must be logged in as a registered member.

Members
Login Now 		Not a member
Free registration
Username
Password
Forgot your password?
 
Remember me